Tumor microenvironment may shape the function and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cells

The Tumor Immunoenvironment

Volumn , Issue , 2013, Pages 361-381

  Jewett, Anahid ^a   Tseng, Han Ching ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

Author keywords

Apoptosis; Cancer stem cells; Differentiation; NF B; NK; Regulation

Indexed keywords

EID: 84905670858     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-6217-6_15     Document Type: Chapter

References (53)

1. Abdulkarim B, Sabri S, Deutsch E et al (2002) Antiviral agent cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers. Oncogene 21(15):2334-2346
2. Azzoni L, Anegon I, Calabretta B, Perussia B (1995) Ligand binding to Fc gamma R induces cmyc-dependent apoptosis in IL-2-stimulated NK cells. J Immunol 154(2):491-499
3. Berlin AL, Paller AS, Chan LS (2002) Incontinentia pigmenti: a review and update on the molecular basis of pathophysiology. J Am Acad Dermatol 47(2):169-187; quiz 88-90
4. Bonavida B, Lebow LT, Jewett A (1993) Natural killer cell subsets: maturation, differentiation and regulation. Nat Immun 12(4-5):194-208
5. Bonavida B, Braquet M, Lebow LT, Jewett A (1994) Qualitative and quantitative analysis of subpopulations of cytotoxic effector cells by flow cytometry. J Lipid Mediat Cell Signal 9(1):19-25
6. Chatenoud L (2003) CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 3(2):123-132
7. Coffelt SB, Hughes R, Lewis CE (2009) Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 1796(1):11-18
8. Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22(11):633-640
9. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991-998
10. Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148
11. Farag SS, Caligiuri MA (2006) Human natural killer cell development and biology. Blood Rev 20(3):123-137
12. Fildes JE, Yonan N, Leonard CT (2008) Natural killer cells and lung transplantation, roles in rejection, infection, and tolerance. Transpl Immunol 19(1):1-11
13. Greten TF, Manns MP, Korangy F (2010) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11(7):802-806
14. Haas P, Loiseau P, Tamouza R et al (2011) NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood 117(3):1021-1029
15. Hu PF, Hultin LE, Hultin P et al (1995) Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased numbers of CD16 ? CD56 ? cells and expansion of a population of CD16dimCD56-cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 10(3):331-340
16. Inagaki A, Soeda A, Oka N et al (2007) Long-term maintenance of brain tumor stem cell properties under at non-adherent and adherent culture conditions. Biochem Biophys Res Commun 361(3):586-592
17. Jewett A, Bonavida B (1994) Activation of the human immature natural killer cell subset by IL-12 and its regulation by endogenous TNF-alpha and IFN-gamma secretion. Cell Immunol 154(1):273-286
18. Jewett A, Bonavida B (1995a) Target-induced anergy of natural killer cytotoxic function is restricted to the NK-target conjugate subset. Cell Immunol 160(1):91-97
19. Jewett A, Bonavida B (1995b) Interferon-alpha activates cytotoxic function but inhibits interleukin-2-mediated proliferation and tumor necrosis factor-alpha secretion by immature human natural killer cells. J Clin Immunol 15(1):35-44
20. Jewett A, Bonavida B (1996) Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol 156(3):907-915
21. Jewett A, Bonavida B (2000) MHC-Class I antigens regulate both the function and the survival of human peripheral blood NK cells: role of endogenously secreted TNF-alpha. Clin Immunol 96(1):19-28
22. Jewett A, Gan XH, Lebow LT, Bonavida B (1996) Differential secretion of TNF-alpha and IFNgamma by human peripheral blood-derived NK subsets and association with functional maturation. J Clin Immunol 16(1):46-54
23. Jewett A, Cavalcanti M, Bonavida B (1997) Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol 159(10):4815-4822
24. Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH (2003) Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol 64(5):505-520
25. Jewett A, Cacalano NA, Teruel A et al (2006a) Inhibition of nuclear factor kappa B (NFkappaB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation. Cancer Immunol Immunother 55(9):1052-1063
26. Jewett A, Cacalano NA, Head C, Teruel A (2006b) Coengagement of CD16 and CD94 receptors mediates secretion of chemokines and induces apoptotic death of naive natural killer cells. Clin Cancer Res 12(7 Pt 1):1994-2003
27. Jewett A, Head C, Cacalano NA (2006c) Emerging mechanisms of immunosuppression in oral cancers. J Dent Res 85(12):1061-1073
28. Jewett A, Teruel A, Romero M, Head C, Cacalano N (2008) Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab0)2 fragment of anti-CD16 antibody. Cancer Immunol Immunother 57(7):1053-1066
29. Jewett A, Arasteh A, Tseng HC et al (2010) Strategies to rescue mesenchymal stem cells (MSCs) and dental pulp stem cells (DPSCs) from NK cell mediated cytotoxicity. PLoS ONE 5(3):e9874
30. Kuss I, Saito T, Johnson JT, Whiteside TL (1999) Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 5(2):329-334
31. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL (1996) Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 2(1):161-173
32. Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL (1999) Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci USA 96(10):5640-5644
33. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231-237
34. Murakami J, Asaumi J, Maki Y et al (2004) Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines. Oncol Rep 12(2):339-345
35. Murakami J, Asaumi J, Kawai N et al (2005) Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemother Pharmacol 56(1):22-28
36. Nemeth E, Baird AW, O'Farrelly C (2009) Microanatomy of the liver immune system. Semin Immunopathol 31(3):333-343
37. Oka N, Soeda A, Inagaki A et al (2007) VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 360(3):553-559
38. Ortaldo JR, Mason AT, O'Shea JJ (1995) Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 181(1):339-344
39. Pasparakis M, Courtois G, Hafner M et al (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417(6891):861-866
40. Patankar MS, Yu J, Morrison JC et al (2005) Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol 1(4):513-523
41. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH (2011) Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 89(2):216-24
42. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ (2002) Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21(55):8404-8413
43. Romagnani C, Juelke K, Falco M et al (2007) CD56brightCD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol 178(8):4947-4955
44. Seitz CS, Lin Q, Deng H, Khavari PA (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95(5):2307-2312
45. Soeda A, Inagaki A, Oka N et al (2008) Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem 283(16):10958-10966
46. Strowig T, Chijioke O, Carrega P et al (2011) Human NK cells of mice with reconstituted human immune system components require preactivation to acquire functional competence. Blood 116(20):4158-4167
47. Tseng HC, Arasteh A, Paranjpe A et al (2010) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS One 5(7):e11590
48. Tseng HC, Arasteh A, Paranjpe A et al (2010b) Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE 5(7):e11590
49. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59(14):3299-3303
50. van Hogerlinden M, Rozell BL, Toftgard R, Sundberg JP (2004) Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J Invest Dermatol 123(1):101-108
51. Vuk-Pavlovic S (2008) Rebuilding immunity in cancer patients. Blood Cells Mol Dis 40(1):94-100
52. Wang T, Niu G, Kortylewski M et al (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48-54
53. Yaguchi T, Sumimoto H, Kudo-Saito C et al (2010) The mechanisms of cancer immunoescape and development of overcoming strategies. Int J Hematol 93(3):294-300